3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
45
Specimen Handling
45
Biopsy
37
Magnetic Resonance Spectroscopy
36
Paclitaxel
22
Nivolumab
21
Carboplatin
21
Gemcitabine
20
Radiosurgery
18
Irinotecan
16
Ipilimumab
13
Cisplatin
13
Capecitabine
12
130-nm albumin-bound paclitaxel
12
trastuzumab deruxtecan
11
Taxes
11
Pemetrexed
11
Cetuximab
11
olaparib
10
Leucovorin
10
Fluorouracil
10
Cyclophosphamide
10
durvalumab
9
Oxaliplatin
9
Bevacizumab
9
abemaciclib
8
X-Rays
8
Fulvestrant
8
Drug Therapy
8
palbociclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
ficlatuzumab
×
90 days
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled